Amylyx Pharmaceuticals, Inc. AMLX 深 滬
交易中 09-20 15:18:31 美东时间
3.235
+0.355
+12.33%
華盛通- 最 高3.28
- 今 開2.90
- 成交量 296.23万股
- 最 低 2.86
- 昨 收 2.88
- 總市值 2.19亿
- 52周最高 19.9488
- 市盈率 靜 4.60
- 換手率 4.37%
- 52周最低 1.575
- 委 比 -94.88%
- 總股本 6778.21万
- 歷史最高 41.9297
- 量 比 2.87
- 振 幅 14.58%
- 歷史最低 1.575
- 每 手 1
- 風險率 7.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying
The Dow Jones index closed higher by over 200 points on Monday. When insiders p...
09-17 21:01
Amylyx Pharmaceuticals GAAP EPS of -$1.07
Amylyx Pharmaceuticals press release (NASDAQ:AMLX): Q2 GAAP EPS of -$1.07. Cash, cash equivalents, and short-term investments were $309.8 million at June 30, 2024, compared to $373.3 million at March ...
08-08 20:48
Amylyx Pharma Q2 2024 Adj. EPS $(0.73), Inline,
Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.73) per share which met the analyst consensus estimate. The company reported quarterly sales of $(1.203 million) which missed the analyst consensus estimate
08-08 19:15
Analyst Ratings For Amylyx Pharma
Analysts' ratings for Amylyx Pharma (NASDAQ:AMLX) over the last quarter vary fr...
07-13 03:01
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a comple...
07-12 21:01
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and congenital hyperinsulinism.
07-11 03:32
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sharecare (SHCR), Amylyx Pharmaceuticals Inc (AMLX) and Biogen (BIIB)
Analysts have been eager to weigh in on the Healthcare sector with new ratings ...
06-24 18:20
Amylyx inks deal to buy Eiger’s GLP-1 targeting drug
Amylyx Pharmaceuticals (NASDAQ:AMLX) has signed an agreement with Eiger BioPharmaceuticals (OTC:EIGRQ) to acquire the rights to the latter’s Phase 3-ready GLP-1 receptor antagonist, Avexitide. Cambrid...
06-22 21:11
ALS therapy market seen increasing to nearly $1.3B by 2029
The market for medicines to treat amyotrophic lateral sclerosis (ALS) in major markets is projected to more than surge to $1.28B in 2029 from $317M in 2019, representing a CAGR of 15%. The rise is due...
06-16 03:37
Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
Amylyx Pharma (NASDAQ:AMLX) underwent analysis by 9 analysts in the last quarte...
05-11 02:01
